Image from Google Jackets

Is there an authoritarian advantage in pandemic response? a comparative case study of China's responses to SARS-CoV-1 (2003) and SARS-CoV-2 (2019)/ Jonathan Schwartz

By: Material type: TextTextPublication details: 2022Subject(s): Online resources: In: Issues and Studies Vol 58, No 2, June 2022, pp.2250001-(1) 2250001-(27) (34)Summary: Effective pandemic response has become an increasingly important focus for research in the face of the COVID-19 pandemic. While there are a number of variables that may be considered as influencing effective response, this paper focuses on the potential impact of an "authoritarian advantage" in achieving an effective response in the period prior to pharmaceutical interventions being available with China as a case study. In essence, this paper explores whether China enjoys an authoritarian advantage, and if so, how it functions. This study compares China's SARS-CoV-1 (2003) response with its SARS-CoV-2 (2019) response by exploring the impact of the authoritarian advantage on the state's ability to effectively engage three key explanatory variables - centralized decision-making powers, public support and media engagement. SARS-CoV-2 is the virus known as severe acute respiratory syndrome coronavirus 2. The disease SARS-CoV-2 causes is COVID-19 (coronavirus disease 2019). SARS-CoV-1 is the virus known as severe acute respiratory syndrome coronavirus 1. It causes SARS (2003).
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Copy number Status Date due Barcode
Journal Article Mindef Library & Info Centre Journals CHINA (Browse shelf(Opens below)) 1 Not for loan 67764.1001

Effective pandemic response has become an increasingly important focus for research in the face of the COVID-19 pandemic. While there are a number of variables that may be considered as influencing effective response, this paper focuses on the potential impact of an "authoritarian advantage" in achieving an effective response in the period prior to pharmaceutical interventions being available with China as a case study. In essence, this paper explores whether China enjoys an authoritarian advantage, and if so, how it functions. This study compares China's SARS-CoV-1 (2003) response with its SARS-CoV-2 (2019) response by exploring the impact of the authoritarian advantage on the state's ability to effectively engage three key explanatory variables - centralized decision-making powers, public support and media engagement. SARS-CoV-2 is the virus known as severe acute respiratory syndrome coronavirus 2. The disease SARS-CoV-2 causes is COVID-19 (coronavirus disease 2019). SARS-CoV-1 is the virus known as severe acute respiratory syndrome coronavirus 1. It causes SARS (2003).

CHINA, COVID-19, HEALTH

There are no comments on this title.

to post a comment.